COVID-19 updates, including vaccine information, for our patients and visitors Learn More

Menu
Search

UC Board of Regents Gives Approval for New Clinical and Translational Research Institute Building on UC San Diego’s La Jolla Campus

 

November 18, 2010  |  

The University of California Board of Regents on Tuesday approved the budget for capital improvements and external financing for the Clinical and Translational Research Institute (CTRI) building, to be constructed on the medical campus of UC San Diego in La Jolla.  The CTRI building will be in close proximity to Thornton Hospital, Moores Cancer Center, the soon-to-open Sulpizio Cardiovascular Center and the recently announced Jacobs Medical Center.

“The CTRI building will create a unique multidisciplinary environment that brings together laboratory scientists and clinical investigators to understand disease, develop new methods of treatment and translate clinical research results into clinical practice,” said Gary S. Firestein, MD, professor of medicine, dean and associate vice chancellor of Translational Medicine and director of the Clinical and Translational Research Institute at UCSD School of Medicine.

The new building, currently slated for completion in late 2016, will comprise 311,000 gsf and 189,000 asf (assignable square feet) including  wet and dry research space, and clinical research space to support investigators in the School of Medicine.

The projected cost of the project is $269 million, which will be primarily paid for with external funding sources rather than state dollars, according to UC San Diego administrators.

# # #

Media Contact: Debra Kain, 619-543-6163, ddkain@ucsd.edu




Media Contact

Share This Article


Related News

3/3/2021
UC San Diego School of Medicine researchers develop an automated process to test city sewage for SARS-CoV-2, allowing them to forecast the region’s COVID-19 caseload one to two weeks ahead of clinical ...
3/2/2021
Researchers at UC San Diego School of Medicine and elsewhere have identified a new drug that could prevent AD by modulating, rather than inhibiting, a key enzyme involved in forming amyloid plaques.
3/2/2021
Researchers at UC San Diego Health see a possible way to detect heart disease through the eye.
3/1/2021
A repurposed drug used to treat arthritis did not significantly improve the outcomes of patients with severe COVID-19 pneumonia. Tocilizumab did not significantly improve clinical status or mortality ...



Follow Us